drugset / Trial / NCT02978326

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326 ↗

Phase 3 Completed 276 enrolled Biogen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 and to evaluate the safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, electrocardiogram (ECG) parameters, and the Columbia Suicide Severity Rating Scale (C-SSRS).

Timeline

Start
2017-01-04
Primary completion
2018-11-15
Completion
2018-12-11

Outcome

Met primary endpoint

paper Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (-17.8 vs -13.6; difference, -4.2; 95% CI, -6.9 to -1.5; P = .003). PMID 34190962 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Zuranolone Small molecule 15 mg Oral
Subject Zuranolone Small molecule 20 mg Oral
Subject Zuranolone Small molecule 30 mg Oral

Indications